TrialsgrambetaRCTs are beautiful

SAFE

2025

Cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab (SAFE trial)

In 262 women with non-metastatic breast cancer receiving anthracycline-based chemotherapy, ramipril, bisoprolol or both for 12 months reduced subclinical cardiac damage at 24 months compared with placebo.

Result

Primary endpoint: Subclinical cardiac damage at 24 months (a fall of ≥10 % in 3D ejection fraction or global longitudinal strain)

3D-LVEF fell by 10.6 % with placebo vs 2.1 % (ramipril), 2.2 % (bisoprolol) and 3.4 % (combination; all p<0.001). Subclinical damage 11.4 % vs 39.3 % with versus without ramipril (p<0.001).

Original publication
Subtopic
Anthracycline cardiotoxicity
Design
2×2 factorial, double-blind, placebo-controlled RCT
Relevance
Supporting: context rather than must-know.
Source
Meattini I, Becherini C, Martella F, et al. ESMO Open. 2025;10(6):105116.doi 10.1016/j.esmoop.2025.105116

Discussion & critique

Modest in size, with an echocardiographic surrogate endpoint and a placebo-arm ejection-fraction decline (10.6 %) far larger than in comparable trials such as PRADA, which raises questions about measurement variability. It is the largest factorial trial of combined ACE-inhibitor plus beta-blocker prophylaxis.